Robert Driscoll

CytomX Therapeutics Inc (NASDAQ: CTMX) reported disappointing third-quarter results and lacks clarity into the path forward for its wholly-owned PD-L1 Probody CX-072, according to Wedbush. The Analyst Wedbush’s Robert Driscoll downgraded CytomX Therapeutics from Outperform to Neutral ...

Arvinas Inc's (NASDAQ: ARVN) two lead assets have a “high likelihood of success” in their respective indications, according to Wedbush. The Analyst Robert Driscoll initiated coverage of Arvinas with an Outperform rating and $38 price target. The Thesis The market seems to...

Cidara Therapeutics Inc (NASDAQ: CDTX) announced a development and commercialization deal Tuesday for its lead antifungal investigational drug, rezafungin. The Analyst Wedbush analyst Robert Driscoll upgraded Cidara from Neutral to Outperform and upped the price target from $2 to $4. The Thesis...

The FDA approved Nabriva Therapeutics PLC – ADR (NASDAQ: NBRV)'s lead antibiotic asset, Xenleta, on Monday for the treatment of community-acquired bacterial infections.  The Analysts Bank of America Merrill Lynch analyst Jason Gerberry reiterated a Buy rating on...

Replimune Group Inc (NASDAQ: REPL)'s lead asset is expected to quickly pass through development and clear the FDA hurdle, according to Wedbush.  The Analyst Robert Driscoll initiated overage of Replimune, which went public in July 2018, with an Outperform rating and $24 price...

Harpoon Therapeutics Inc (NASDAQ: HARP), a clinical-stage immunotherapy company working on therapies for solid tumors and hematological malignancies, recently offered 5.4 million shares in an IPO, pricing the shares at $14 each.  The Analyst Following the expiration of the IPO quiet period,...

Wedbush analysts see an attractive entry point for Alpine Immune Sciences Inc. (NASDAQ: ALPN), as the biotech's initial candidates will enter the clinic over the next year. The Analyst Robert Driscoll of Wedbush initiated coverage on Apline with an Outperform rating and $13 price target....

While Wedbush predicts Arbutus Biopharma Corp (NASDAQ: ABUS) shares will appreciate over the next six-to-12 months amid clinical data readouts, the sell-side firm stepped to the sidelines following the Canadian biopharma company's fourth-quarter print and and expectations of limited near-...

Clinical stage biopharma company resTORbio, Inc. (NASDAQ: TORC)'s TORC1 inhibition program uses a protein called serine/threonine kinase that aims to regulate aging and aging-related diseases conditions without undesirable side effects. The Analyst Wedbush analyst Robert Driscoll...